Abstract
Background:
Antiretroviral therapy (ART) has improved lifespan and quality of life of patients infected with the HIV-1. However, ART has several potential limitations, including the development of drug resistance and suboptimal penetration to selected anatomic compartments. Improving the delivery of antiretroviral molecules could overcome several of the limitations of current ART.
Results & conclusion:
Two to ten nanometer diameter inorganic gold crystals serve as a base scaffold to combine molecules with an array of properties in its surface. We show entry into different cell types, antiviral activity of an HIV integrase inhibitor conjugated in a gold nanoparticle and penetration into the brain in vivo without toxicity. Herein, gold nanoparticles prove to be a promising tool to use in HIV therapy.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / chemical synthesis
-
Anti-HIV Agents / chemistry*
-
Brain / metabolism
-
Drug Carriers / chemistry*
-
Endothelial Cells / cytology
-
Endothelial Cells / drug effects
-
Endothelial Cells / metabolism
-
Female
-
Gold / chemistry*
-
HIV Core Protein p24 / antagonists & inhibitors
-
HIV Core Protein p24 / metabolism
-
HIV Infections / drug therapy
-
HIV-1 / physiology*
-
Humans
-
Leukocytes, Mononuclear / cytology
-
Leukocytes, Mononuclear / drug effects
-
Leukocytes, Mononuclear / metabolism
-
Macrophages / cytology
-
Macrophages / drug effects
-
Macrophages / metabolism
-
Metal Nanoparticles / chemistry*
-
Metal Nanoparticles / toxicity
-
Metal Nanoparticles / ultrastructure
-
Mice
-
Mice, Inbred BALB C
-
Raltegravir Potassium / administration & dosage
-
Raltegravir Potassium / chemical synthesis
-
Raltegravir Potassium / chemistry
-
Tissue Distribution
-
Virus Replication / drug effects
Substances
-
Anti-HIV Agents
-
Drug Carriers
-
HIV Core Protein p24
-
Raltegravir Potassium
-
Gold